Literature DB >> 12604558

Antianaerobe activity of RBX 7644 (ranbezolid), a new oxazolidinone, compared with those of eight other agents.

Lois M Ednie1, Ashok Rattan, Michael R Jacobs, P C Appelbaum.   

Abstract

The activity of ranbezolid (RBX 7644), a new oxazolidinone, against 306 anaerobes was compared with those of 11 other agents. The MICs at which 50% of the isolates tested are inhibited and those at which 90% of the isolates tested are inhibited (in micrograms per milliliter) were as follows: ranbezolid, 0.03 and 0.5; linezolid, 2 and 4; vancomycin, >16 and >16; teicoplanin, 1 and >16; quinupristin-dalfopristin, 1 and >8; amoxicillin-clavulanate, 0.5 and 2; imipenem, 0.125 and 1; clindamycin, 0.25 and 8; metronidazole, 1 and 4; gatifloxacin, 0.5 and 4; and moxifloxacin, 0.5 and 2, respectively. Ranbezolid had very good in vitro activity against both gram-negative and -positive anaerobes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12604558      PMCID: PMC149336          DOI: 10.1128/AAC.47.3.1143-1147.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  Comparative antianaerobic activity of BMS 284756.

Authors:  D B Hoellman; L M Kelly; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

Review 2.  Quinupristin/dalfopristin and linezolid: where, when, which and whether to use?

Authors:  D M Livermore
Journal:  J Antimicrob Chemother       Date:  2000-09       Impact factor: 5.790

3.  Anti-anaerobic activity of AZD2563, a new oxazolidinone, compared with eight other agents.

Authors:  Lois M Ednie; Michael R Jacobs; Peter C Appelbaum
Journal:  J Antimicrob Chemother       Date:  2002-07       Impact factor: 5.790

4.  Beta-lactamase production and susceptibilities to amoxicillin, amoxicillin-clavulanate, ticarcillin, ticarcillin-clavulanate, cefoxitin, imipenem, and metronidazole of 320 non-Bacteroides fragilis Bacteroides isolates and 129 fusobacteria from 28 U.S. centers.

Authors:  P C Appelbaum; S K Spangler; M R Jacobs
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

5.  The in-vitro activity of linezolid (U-100766) and tentative breakpoints.

Authors:  R Wise; J M Andrews; F J Boswell; J P Ashby
Journal:  J Antimicrob Chemother       Date:  1998-12       Impact factor: 5.790

6.  Activities of gatifloxacin compared to those of seven other agents against anaerobic organisms.

Authors:  L M Ednie; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

7.  Linezolid activity compared to those of selected macrolides and other agents against aerobic and anaerobic pathogens isolated from soft tissue bite infections in humans.

Authors:  E J Goldstein; D M Citron; C V Merriam
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

8.  Susceptibilities of 394 Bacteroides fragilis, non-B. fragilis group Bacteroides species, and Fusobacterium species to newer antimicrobial agents.

Authors:  P C Appelbaum; S K Spangler; M R Jacobs
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

9.  Susceptibility of 539 gram-positive and gram-negative anaerobes to new agents, including RP59500, biapenem, trospectomycin and piperacillin/tazobactam.

Authors:  P C Appelbaum; S K Spangler; M R Jacobs
Journal:  J Antimicrob Chemother       Date:  1993-08       Impact factor: 5.790

Review 10.  Oxazolidinones: a review.

Authors:  D I Diekema; R N Jones
Journal:  Drugs       Date:  2000-01       Impact factor: 11.431

View more
  8 in total

1.  Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species.

Authors:  Kim L Credito; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

2.  Clinical and microbiological characteristics of Eggerthella lenta bacteremia.

Authors:  B J Gardiner; A Y Tai; D Kotsanas; M J Francis; S A Roberts; S A Ballard; R K Junckerstorff; T M Korman
Journal:  J Clin Microbiol       Date:  2014-12-17       Impact factor: 5.948

Review 3.  Gatifloxacin: a review of its use in the treatment of bacterial infections in the US.

Authors:  Susan J Keam; Katherine F Croom; Gillian M Keating
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  Mode of action of Ranbezolid against staphylococci and structural modeling studies of its interaction with ribosomes.

Authors:  Vandana Kalia; Rajni Miglani; Kedar P Purnapatre; Tarun Mathur; Smita Singhal; Seema Khan; Sreedhara R Voleti; Dilip J Upadhyay; Kulvinder Singh Saini; Ashok Rattan; V Samuel Raj
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

5.  Activities of tizoxanide and nitazoxanide compared to those of five other thiazolides and three other agents against anaerobic species.

Authors:  Glenn A Pankuch; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

6.  In vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infections.

Authors:  Charles E Edmiston; Candace J Krepel; Gary R Seabrook; Lewis R Somberg; Atilla Nakeeb; Robert A Cambria; Jonathan B Towne
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

7.  Moxifloxacin in the treatment of skin and skin structure infections.

Authors:  David Rp Guay
Journal:  Ther Clin Risk Manag       Date:  2006-12       Impact factor: 2.423

Review 8.  Linezolid Resistance in Staphylococci.

Authors:  Stefania Stefani; Dafne Bongiorno; Gino Mongelli; Floriana Campanile
Journal:  Pharmaceuticals (Basel)       Date:  2010-06-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.